Elanco Animal Health Incorporated (ELAN)
ELAN trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1739104/000173910426000012/0001739104-26-000012-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ELAN on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001739104 |
| SEC industry code | Pharmaceutical Preparations |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $4.7B |
| Net income | -$232.0M |
| Operating income | Not in SEC XBRL data |
| Net margin | -4.9% |
| Operating margin | Operating income not reported |
| Revenue growth | +6.2% |
| Cash | $545.0M |
| Total assets | $13.4B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-06 |
| Cash and burn | $465.0M cash; operating cash flow $153.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 499,827,067 (2026-11-04); 496,863,473 a year earlier; 492,798,113 three years earlier. | Cover page 2026-11-04 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Indianapolis, Indiana, United States | PCAOB Form AP 2026-03-13 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $2.6M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $1.3B | $18.0M | $216.0M | $465.0M | $3.4B | $5.1B | 10-Q 2026-11-06 |
| Q2 2026 2026-06-30 | $1.4B | $54.0M | $277.0M | $530.0M | $3.7B | $5.0B | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $1.4B | $57.0M | $13.0M | $428.0M | $3.7B | $4.9B | 10-Q 2026-05-06 |
| Q4 2025 2025-12-31 | $1.1B | -$276.0M | $108.0M | $545.0M | $3.8B | $4.7B | 10-K 2026-02-24 |
| Q3 2025 2025-09-30 | $1.1B | -$34.0M | $219.0M | $505.0M | $3.8B | $4.6B | 10-Q 2026-11-06 |
| Q2 2025 2025-06-30 | $1.2B | $11.0M | $237.0M | $539.0M | $4.0B | $4.5B | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $1.2B | $67.0M | -$4.0M | $487.0M | $4.4B | $4.4B | 10-Q 2026-05-06 |
| Q4 2024 2024-12-31 | $1.0B | -$8.0M | $177.0M | $468.0M | $4.3B | $4.4B | 10-K 2026-02-24 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B7 | 2020-12-02 |
| Latest annual report 10-K FOR THE YEAR ENDED DECEMBER 31, 2025 | 10-K | 2026-02-24 |
| Latest quarterly / interim 10-Q FOR THE PERIOD ENDED SEPTEMBER 30, 2026 | 10-Q | 2026-11-06 |
| Latest current report 8-K DATED NOVEMBER 6, 2026 | 8-K | 2026-11-06 |
| Latest proxy | DEFA14A | 2026-04-08 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +4.0% |
| 1 month | +19.5% |
| 3 months | +19.0% |
| Year to date | +18.3% |
| 1 year | +21.8% |
| From 52-week high | -0.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RDY | Dr. Reddy's Laboratories Ltd | $14.70 | -0.27% | $12.3B |
| BBIO | BridgeBio Pharma Inc. | $77.36 | -1.20% | $15.1B |
| JAZZ | Jazz Pharmaceuticals plc Common Stock (Ireland) | $239.77 | -0.74% | $15.4B |
| BMRN | BioMarin Pharmaceutical Inc. | $57.99 | +1.33% | $11.2B |
| MDGL | Madrigal Pharmaceuticals Inc. | $423.96 | -0.80% | $9.8B |
| ASND | Ascendis Pharma A/S Ordinary Share | $271.73 | -1.33% | $17.9B |
| TGTX | TG Therapeutics Inc. | $62.76 | -2.71% | $9.5B |
| SMMT | Summit Therapeutics Inc. Common Stock | $11.82 | -16.47% | $9.5B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier